Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712074 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT01712074 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 186 participants.
The verdict
NCT01712074, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
This study will evaluate safety and efficacy of PF-05212377 in subjects with mild-to-moderate Alzheimer's Disease with existing neuropsychiatric symptoms on a stable dose of Donepezil. The 4-week run-in will minimize placebo effect. The 12-week treatment period is considered the minimum length necessary to reliably evaluate the effect PF-05212377 on cognition and and neuropsychiatric symptoms in this population. The 2-week washout will allow to monitor re-emergence of neuropsychiatric and cognitive symptoms.
Interventions
- OTHER Placebo
- DRUG PF-05212377 (SAM-760)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712074
The ClinicalTrials.gov registry entry for NCT01712074 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01712074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712074 about?
NCT01712074 is a clinical study titled "Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil". This study will evaluate safety and efficacy of PF-05212377 in subjects with mild-to-moderate Alzheimer's Disease with existing neuropsychiatric symptoms on a stable dose of Donepezil. The 4-week run-in will minimize placebo effect. The 12-week treatment period is considered the minimum length neces...
What is the current status of trial NCT01712074?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2012-11. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01712074?
The interventions under investigation include: Placebo (OTHER), PF-05212377 (SAM-760) (DRUG).
Who is sponsoring clinical trial NCT01712074?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.